CHF trial mythbusting, page-28

It was actually going to potentially cost Teva up to US$500m to complete all its contractual obligations i.e. complete the trial, then to establish a NEW marketing and sales team just for CHF. Read the lodge partners article for an example of how they could be obligated to spend US$500m to get the product out to market.

Not to mention the $1bn milestone payment they would have had to pay MSB.

Remember Teva are a generic drug company ... stem cells and CHF are way outside their normal remit. They would need new infrastructure and teams along each step of the way. What MSB need, is a partner that has it all set up - which only exists if the partner is already in that field of medicine.

The above figures are just estimates, but gives you an idea.

So its not just US$50m Teva were up for, it could be up to $1.5bn.